Back to search

Article

Glioblastoma mutations impair ligand discrimination by EGFR

2021-05-04

Abstract excerpt

<h4>SUMMARY</h4> The epidermal growth factor receptor (EGFR) is frequently mutated in human cancer, and is an important therapeutic target. EGFR inhibitors have been successful in lung cancer, where the intracellular tyrosine kinase domain is mutated, but not in glioblastoma multiforme (GBM) – where mutations (or deletions) occur exclusively in the EGFR extracellular region. Wild-type EGFR is known to elicit dist...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ded5ac5d-d959-5670-981d-eac85d89e366
DOI
10.1101/2021.05.04.442654
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Glioblastoma mutations impair ligand discrimination by EGFRDOI 10.1101/2021.05.04.442654
Select a neighboring publication to make it the new centre.